Literature DB >> 350471

Why monitor serum levels of gentamicin?

M Barza, M Lauermann.   

Abstract

Although it is widely recommended that serum levels of aminoglycoside antibiotics be monitored by assay, the justification for this approach has not been clearly presented. A number of studies indicate that serum levels of these agents cannot be predicted reliably on the basis of simple dosage formulae; the major confounding factors being abnormalities of renal function and of extracellular fluid volume in addition to less well defined variables such as fever and anaemia. The influence of haemodialysis and concomitant administration of carbenicillin further complicate dosage estimations in patients with renal insufficiency. On the basis of currently available data, it is reasonable to suggest an optimum range of 5 to 8 microgram/ml for peak serum levels of gentamicin. There are no reliable studies from which to derive a comparable value for trough (pre-dose) concentrations. The relative importance of peak and trough values for nephrotoxicity and ototoxicity is an unresolved subject of controversy. However, it seems possible that neither of these individual values, but rather the 'area under the time-concentration curve' is the major risk factor for toxicity. In view of the unpredictability of serum levels, especially in seriously ill patients in a fluctuating physiological state, periodical serum gentamicin assays should be performed. The main objective of these assays is to ensure that the peak serum levels attained are adequate, but not unnecessarily high.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 350471     DOI: 10.2165/00003088-197803030-00002

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  95 in total

1.  Alleged effect of bile constituents on gentamicin assays.

Authors:  D R McDonald; P M Waterworth
Journal:  Antimicrob Agents Chemother       Date:  1974-06       Impact factor: 5.191

2.  Concentrations of gentamicin and amikacin in human kidneys.

Authors:  C Q Edwards; C R Smith; K L Baughman; J F Rogers; P S Lietman
Journal:  Antimicrob Agents Chemother       Date:  1976-06       Impact factor: 5.191

3.  Infections in cancer patients. Results with gentamicin sulfate therapy.

Authors:  G P Bodey; E Middleman; T Umsawadi; V Rodriguez
Journal:  Cancer       Date:  1972-06       Impact factor: 6.860

4.  The unpredictability of serum concentrations of gentamicin: pharmacokinetics of gentamicin in patients with normal and abnormal renal function.

Authors:  D Kaye; M E Levison; E D Labovitz
Journal:  J Infect Dis       Date:  1974-08       Impact factor: 5.226

5.  Gentamicin in newborn infants. Comparison of intramuscular and intravenous administration.

Authors:  J W Paisley; A L Smith; D H Smith
Journal:  Am J Dis Child       Date:  1973-10

6.  Gentamicin intravenous infusion rate: effect on interstitial fluid concentration.

Authors:  A J Kozak; D N Gerding; L R Peterson; W H Hall
Journal:  Antimicrob Agents Chemother       Date:  1977-11       Impact factor: 5.191

7.  Gas-liquid chromatographic method for the assay of aminoglycoside antibiotics in serum.

Authors:  J W Mayhew; S L Gorbach
Journal:  J Chromatogr       Date:  1978-04-11

8.  Activity of five aminoglycoside antibiotics in vitro against gram-negative bacilli and Staphylococcus aureus.

Authors:  L S Young; W L Hewitt
Journal:  Antimicrob Agents Chemother       Date:  1973-12       Impact factor: 5.191

9.  In vitro evaluation of a new aminoglycoside derivative of kanamycin, a comparison with tobramycin and gentamycin.

Authors:  K Ries; M E Levison; D Kaye
Journal:  Antimicrob Agents Chemother       Date:  1973-04       Impact factor: 5.191

10.  Pharmacology of gentamicin in the biliary tract of humans.

Authors:  J Mendelson; J Portnoy; H Sigman
Journal:  Antimicrob Agents Chemother       Date:  1973-11       Impact factor: 5.191

View more
  35 in total

Review 1.  Aminoglycoside-induced hearing loss in humans.

Authors:  R E Brummett; K E Fox
Journal:  Antimicrob Agents Chemother       Date:  1989-06       Impact factor: 5.191

2.  Pharmacokinetic analysis of amikacin twice and single daily dosage in immunocompromised pediatric patients.

Authors:  N Krivoy; S Postovsky; R Elhasid; M W Ben Arush
Journal:  Infection       Date:  1998 Nov-Dec       Impact factor: 3.553

3.  Extended-interval gentamicin dosing in achieving therapeutic concentrations in malaysian neonates.

Authors:  Yee Shan Low; Sin Li Tan; Angeline Sl Wan
Journal:  J Pediatr Pharmacol Ther       Date:  2015 Mar-Apr

4.  Population pharmacokinetics of tobramycin.

Authors:  L Aarons; S Vozeh; M Wenk; P Weiss; F Follath
Journal:  Br J Clin Pharmacol       Date:  1989-09       Impact factor: 4.335

Review 5.  Use of aminoglycosides in elderly patients. Pharmacokinetic and clinical considerations.

Authors:  K Mörike; M Schwab; U Klotz
Journal:  Drugs Aging       Date:  1997-04       Impact factor: 3.923

Review 6.  Clinical pharmacokinetics of aminoglycoside antibiotics.

Authors:  J C Pechere; R Dugal
Journal:  Clin Pharmacokinet       Date:  1979 May-Jun       Impact factor: 6.447

Review 7.  Antibiotic trials in intra-abdominal infections. A critical evaluation of study design and outcome reporting.

Authors:  J S Solomkin; J L Meakins; M D Allo; E P Dellinger; R L Simmons
Journal:  Ann Surg       Date:  1984-07       Impact factor: 12.969

8.  Hemodialysis elimination rates and clearance of gentamicin and tobramycin.

Authors:  G R Matzke; C E Halstenson; W F Keane
Journal:  Antimicrob Agents Chemother       Date:  1984-01       Impact factor: 5.191

9.  Increased aminoglycoside dosage requirements in hematologic malignancy.

Authors:  R G Zeitany; N S El Saghir; C R Santhosh-Kumar; M A Sigmon
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

10.  Increase of amikacin half-life during therapy in patients with renal insufficiency.

Authors:  J Blaser; S Rüttimann; H Bhend; R Lüthy
Journal:  Antimicrob Agents Chemother       Date:  1983-06       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.